MTW Research and Development

Your final fact of the week as we celebrate Clinicsl Trials Day today. 😎

The MTW Ophthalmology Team took part in a clinical trial of a new drug for Retinal Vein Occlusion called Faricimab. Shortly after recruitment finished, Faricimab was approved for use by the US Food and Drug administration for Diabetic Macula Oedema and Wet Age-Related Macular Degeneration. 🌟